NasdaqCM:SLNOBiotechs
What Soleno Therapeutics (SLNO)'s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders
Soleno Therapeutics recently highlighted what it called a transformational 2025 for VYKAT XR, pointing to strong preliminary revenue and plans to release full financial results in late February.
The company is also preparing for a series of investor conferences beginning 12 February, which could further spotlight its rare disease portfolio, including Diazoxide Choline Extended-Release tablets in Phase III trials for Prader-Willi Syndrome.
We’ll now examine how enthusiasm around VYKAT XR’s...